XERS
Company Description
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M | 20.43M | 2.72M | 2.46M | 1.56M | 1.07M |
| Net Income | 554,000 | (54.84M) | (62.26M) | (94.66M) | (122.72M) | (91.14M) | (125.58M) | (60.08M) | (26.55M) | (13.21M) |
| EPS | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 | -3.49 | -4.99 | -13.09 | -7.17 |
| Free Cash Flow | 27.93M | (37.85M) | (49.29M) | (103.42M) | (96.62M) | (80.94M) | (80.94M) | (57.79M) | (25.36M) | (16.12M) |
| FCF / Share | 0.17 | -0.26 | -0.36 | -0.76 | -1.22 | -1.90 | -3.10 | -4.80 | -12.51 | -8.75 |
| Operating CF | 28.63M | (36.98M) | (47.02M) | (102.89M) | (95.53M) | (80.56M) | (80.56M) | (56.28M) | (24.66M) | (16.09M) |
| Total Assets | 383.53M | 323.06M | 322.60M | 344.52M | 304.36M | 159.15M | 108.99M | 120.03M | 45.00M | 33.53M |
| Total Debt | 37.76M | 271.45M | 229.19M | 198.06M | 88.07M | 87.02M | 58.30M | 31.89M | 0 | 0 |
| Cash & Equiv | 111.04M | 71.62M | 67.45M | 121.97M | 67.27M | 37.60M | 19.52M | 45.72M | 42.05M | 32.27M |
| Book Value | 13.69M | (29.61M) | (6.78M) | 45.19M | 95.23M | 33.76M | 14.44M | 75.41M | (57.83M) | (31.93M) |
| Return on Equity | 0.04 | N/A | N/A | -2.09 | -1.29 | -2.70 | -8.70 | -0.80 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.10M | 83.13M | 85.81M | 74.38M | 71.54M | 60.12M | 60.10M | 54.27M | 48.06M | 40.64M | 44.39M | 48.32M |
| Net Income | (31.10M) | 2.23M | 11.08M | 621,000 | (1.93M) | (9.22M) | (5.11M) | (15.74M) | (15.01M) | (18.98M) | (13.39M) | (12.19M) |
| EPS | -0.18 | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 | -0.03 | -0.11 | -0.10 | -0.14 | -0.10 | -0.09 |
| Free Cash Flow | 8.05M | 9.54M | 19.71M | 18.07M | (97,000) | (10.04M) | 1.75M | (8.39M) | (10.74M) | (20.47M) | 6.15M | (14.96M) |
| FCF / Share | 0.05 | 0.06 | 0.12 | 0.10 | -0.00 | -0.07 | 0.01 | -0.06 | -0.07 | -0.15 | 0.04 | -0.11 |
| Operating CF | 8.26M | 9.87M | 20.04M | 18.43M | 182,000 | (10.03M) | 1.98M | (8.30M) | (10.35M) | (20.30M) | 6.29M | (14.61M) |
| Total Assets | 411.90M | 392.01M | 383.53M | 370.19M | 334.69M | 315.45M | 323.06M | 321.10M | 331.73M | 336.62M | 322.60M | 327.78M |
| Total Debt | 289.44M | 37.33M | 37.76M | 38.19M | 257.22M | 268.75M | 271.45M | 270.96M | 269.80M | 268.69M | 229.19M | 227.94M |
| Cash & Equiv | 121.75M | 111.75M | 111.04M | 91.60M | 59.28M | 58.44M | 71.62M | 59.23M | 57.60M | 62.69M | 67.45M | 46.14M |
| Book Value | (9.73M) | 13.01M | 13.69M | (861,000) | (19.30M) | (35.13M) | (29.61M) | (28.32M) | (19.29M) | (9.18M) | (6.78M) | 3.87M |
| Return on Equity | N/A | 0.17 | 0.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -3.15 |
